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89Introduction: Cobalamin C (cblC) deﬁciency is the most common inborn error of vitamin B12 metabolism.
Renal failure attributed to thrombotic microangiopathy (TMA) has occasionally been described in the late-
onset presentation of cblC deﬁciency, but kidney lesions associated with cblC deﬁciency remain poorly
deﬁned. This study aims to describe the characteristics of kidney disease in cblC deﬁciency, and to provide
a comparative histological analysis with cblC-independent renal TMA.
Methods: We performed a multicenter retrospective study including 7 patients with cblC deﬁciency and 16
matched controls with cblC-independent TMA. The patients included were aged 6 to 26 years at the time of
the ﬁrst manifestations. All patients presented with acute renal failure, proteinuria, and hemolysis; 5 pa-
tients required dialysis.
Results: The histological study revealed arteriolar and glomerular TMA in all patients. After comparison
with the cblC-independent TMA control group, a vacuolated aspect of the glomerular basement mem-
brane and the intensity of glomerular capillary wall IgM deposits were more present in cblC deﬁciency
patients than in controls. Six patients were treated with hydroxycobalamin. All of them improved, with
disappearance of hemolysis, and 3 of the 4 patients requiring renal replacement therapy were weaned off
dialysis.
Conclusion: This study provides a precise description of kidney pathology in cblC deﬁciency. Due to major
therapeutic implications, we suggest that patients with renal TMA be screened for cblC deﬁciency
regardless of age, particularly when the kidney biopsy provides evidence of long-lasting TMA, including a
vacuolated aspect of the glomerular basement membrane and glomerular capillary wall IgM deposition.
Kidney Int Rep (2018) -, -–-; https://doi.org/10.1016/j.ekir.2018.05.015
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FLA 5.5.0 DTD  EKIR368_proof  30Typical HUS is due to a verocytotoxin commonly
secreted by Escherichia coli O157:H7, whereas TTP is
caused by deﬁciency of von Willebrand factor protease
(ADAMTS 13). Other causes of TMA include atypical
HUS, resulting from uncontrolled activation of the
alternative pathway of complement, malignant hyper-
tension, drugs, or malignancies.1,2 Familial TMA has
been identiﬁed in patients with cobalamin C
deﬁciency.
Methylmalonic aciduria (MMA) and homocystinuria
cblC type, also named cblC deﬁciency, is the most1
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191common inborn error of intracellular vitamin B12
metabolism. This autosomal recessive disease, due to
mutations in MMACHC (methylmalonic aciduria cblC
type with homocystinuria) gene,3 leads to a defect in
the synthesis of the 2 active coenzyme derivatives of
cobalamin (Cbl), adenosylcobalamin (AdoCbl) and
methylcobalamin (MeCbl). The substance AdoCbl acts
as a cofactor for the mitochondrial L-methylmalonyl-
coenzyme A (CoA) mutase (MMA mutase) during the
transformation of methylmalonyl-CoA in succinyl-CoA,
whereas MeCbl is required for the intracytoplasmic
methylation of homocysteine in methionine by the
methionine synthase (Figure 1). Two distinct pheno-
types of cblC disease have been described, differing in
age at presentation, symptoms, and outcomes.4 The
most frequent is the early-onset disease, characterized
by failure to thrive, neurologic deterioration, and he-
matologic abnormalities during the ﬁrst year of life.5
The late-onset forms are rarer, usually less severe,
and revealed by neuropsychiatric symptoms, pulmo-
nary arterial hypertension (PAH), HUS, or myelopathy.
Although timely recognition of cblC deﬁciency is of
the utmost importance because it has speciﬁc thera-
peutic implications, the kidney lesions in this setting
are poorly described, due to the limited number of
cases available and the absence of a speciﬁc study.6 In
this context, the identiﬁcation of characteristic kidney
lesions encountered in cblC deﬁciency would be help-
ful for pathologists and nephrologists to identify this
frequently misdiagnosed entity.
The present study provides a systematic retrospec-
tive description of the histopathological ﬁndings on
kidney biopsy in cblC deﬁciency, and a comparative
analysis of renal lesions in cblC deﬁciency patients and
in matched TMA control patients.Figure 1. Intracellular cobalamin metabolism. AdoCbl, adenosylcobalamin
2
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Study Population and Data Collection
We performed a multicenter retrospective study in 7
patients with proven cblC deﬁciency and available
kidney biopsy. The cases were selected in 6 different
centers in France and Belgium. The diagnosis of cblC
deﬁciency was made by complementation studies or
genetic testing. The data collected included clinical
(age, hypertension, edema, PAH, neurologic symptoms,
and thromboembolic events), biological (hemoglobin,
platelets, schizocytes, lactate dehydrogenase [LDH],
haptoglobin, plasma creatinine, estimated glomerular
ﬁltration rate (eGFR), proteinuria, and complement
system), and biochemical (vitamin B12, total homo-
cysteinemia, MMA, and methioninemia) characteristics
at initial presentation. The management and the
outcome of each patient were also recorded.
The cblC cases were compared with controls with
TMA of cblC-independent origin. The controls were
selected in 2 different centers (Rouen University Hos-
pital, France, and Necker Hospital, Paris, France). We
included all of the patients aged 4 to 28 years who
presented between 1999 and 2015 with available kid-
ney biopsy ﬁndings revealing renal TMA. Patients
with TMA lesions associated with IgA nephropathy or
lupus nephritis were excluded. Data on age, protein-
uria, eGFR, and cause of TMA were collected for each
control.
The eGFR was calculated based on the Modiﬁcation
of Diet in Renal Disease (MDRD) formula for
adults and the Schwartz formula for children and
adolescents.
All of the research procedures were approved by the
local ethics committee of Rouen, France (E2015-36).; Cbl, cobalamin; MeCbl, methylcobalamin; MMACHC Q12, ---.
Kidney International Reports (2018) -, -–-
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
June 2018  2:36 pm  ce
Q3
4
Q11
M Lemoine et al.: cblC Deﬁciency’s Histological Pattern CLINICAL RESEARCH
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280Kidney Pathology
Kidney biopsy specimens from the cblC patients and
control patients were collected. A centralized review of
all the biopsy ﬁndings was performed in a blinded
manner by an experienced pathologist and a nephrol-
ogist of Rouen University Hospital. Masson trichrome,
hematoxylin/eosin/saffron, and Jones methenamine
silver stainings were used to assess glomerular,
vascular (interlobular arteries and juxtaglomerular ar-
terioles) and tubulo-interstitial lesions. The severity of
each lesion was quantiﬁed as following: 0 (no lesion), 1
(light), 2 (moderate), and 3 (severe). The reports of the
immunoﬂuorescence study were collected from each
center. Intensity of immunoﬂuorescence was quoted
from 0 to 3. Ultrastructural electron microscopy was
performed in 1 patient.281
282
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284
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288Statistical Analysis
Quantitative variables are expressed as mean  SD and
were compared with the MannWhitney U test,
whereas qualitative variables are expressed in numbers
and percentages and were compared with the Fisher
exact test. A P value of <0.05 was considered statis-
tically signiﬁcant.Table 1. Clinical, biological, and biochemical characteristics of the 7 cas
Patient 1 (7) Patient 2 (7) Patient
Clinical presentation
Age (yr) 18 18 20
Hypertension Yes Yes Yes
Edema Yes No Yes
PAH No Yes No
Neurologic symptoms Yes No No
Thromboembolic event No No No
Biology
Hemoglobin (g/dl) 7.8 12.5 11.6
Platelets (g/l) 141 191 101
Schizocytes Yes Yes Yes
LDH (UI/l) 787 444 104
Haptoglobin (mmol/l) < 0.1 NA < 0.
Creatinine (mmol/l) Dialysis Dialysis Dialy
eGFR (ml/min per 1.73 m2)
Proteinuria (g/24 h) 6 2 1.3
C3 Normal NA Norm
C4 Normal NA Norm
Complement alternative pathway Normal NA Norm
Biochemistry
Vitamin B12 (pg/ml) 558 NA 500
Total plasma homocysteine (mmol/l) 73 NA 185
Urine MMA (mmol/mmol) NA NA 244
Plasma methionine (mmol/l) 17 NA 4
Complementation study No No No
Genetic study of MMACHC
Mutation 1 c.271dupA c.271dupA c.271d
Mutation 2 c.82-9_12delTTTC c.82-9_12delTTTC c.389A
EGFR, estited glomerular ﬁltration rate; LDH, lactate dehydrogenase; MMA, methylmalonic aci
Kidney International Reports (2018) -, -–-
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Baseline Characteristics
Seven patients with cblC deﬁciency and available
kidney biopsy were included. Five of them were pre-
viously reported.7–9 Their baseline characteristics are
described in Table 1. All the patients presented with
late-onset disease and the age at initial presentation
varied from 6 to 26 years. Familial disease was noted in 2
sets of siblings (patients 1 and 27 and patients 4 and 58 Q).
All but 1 patient had hypertension, and 4 had edema.
Only 1 patient had a history of neurological disorder
(language delay), 1 had experienced a thromboembolic
event, and 1 had PAH.
All of the patients presented with hemolysis, but 4
of them had a normal platelet level. Five patients
required renal replacement therapy, and only 1 patient
had an eGFR >30 ml/min per 1.73 m2. Proteinuria was
present in all tested patients and ranged from 1.3 to 9.0
g/d. All of the patients had normal C3 and C4 levels,
but patient 4 had a heterozygous mutation in comple-
ment factor H.
Total homocysteine varied from 44 to 230 mmol/l
(normal<13 mmol/l10) and urine methylmalonic acid from
19 to 244mmol/mmol creatinine (normal<4mmol/mmol10).es at initial presentation
3 (9) Patient 4 (8) Patient 5 (8) Patient 6 Patient 7
6 8.5 15 26
Yes No Yes Yes
Yes No No Yes
No No No No
No No No No
Yes No No No
7.2 11.5 8.9 7.0
330 440 128 74
No No No No
4 NA NA 1021 3000
1 0.1 0.2 < 0.2 < 0.1
sis Dialysis 55 Dialysis 290
110 18
1.6 4.8 9 7
al Normal Normal Normal Normal
al Normal Normal Normal Normal
al Factor H mutation Normal Normal Normal
600 550 580 1082
104 44 97 230
19 22,5 91 83
30 30 40 NA
Yes Yes No Yes
upA c.271dupA c.271dupA c.271dupA c.271dupA
>G c.82-9_12delTTTC c.82-9_12delTTTC c.82-9_12delTTTC c.389A>G
d; NA, not available; PAH, pulmonary hypertension.
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384
385Plasma methionine was decreased in 1 tested patient
(patient 3) (normal 1137 mmol/l). Patient 5, who had the
lowest homocysteine concentration, was diagnosed early,
when she had only proteinuria without kidney failure or
extrarenal manifestation.
Genetic analysis of MMACHC was available in all
patients, revealing compound heterozygosity for the
frameshift mutation c.271dupA, together with the
splice mutation c.82-9_12delTTTC in patients 1, 2, 4, 5,
and 6, and the missense mutation c.389A>G
(p.Tyr130Cys) in patients 3 and 7. In 3 patients, the
diagnosis was also based on complementation analysis
in ﬁbroblasts (patients 4, 5, and 7).6
386
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404Management and Outcomes
Patient management and outcomes are presented in
Table 2. Time between the ﬁrst presentation and the
treatment initiation varied from 10 days to 7 years. One
patient was not treated and died of pulmonary veino-
occlusive disease at 18 years of age (patient 2). Au-
topsy showed pulmonary capillary hemangiomatosis
and renal TMA. The diagnosis was made 15 years later,
when his brother (patient 1) was diagnosed. The 6
other patients were treated with parenteral hydrox-
ycobalamin (OHCbl), betaine, and folinic acid. All of
them improved, with disappearance of hemolysis.
Three of the 4 patients requiring renal replacement
therapy were weaned off dialysis. The fourth received
a kidney transplant 1 year after the diagnosis.
Four patients were treated by plasma exchanges
before diagnosis, and 3 of them improved temporarilyTable 2. Management and outcomes of the 7 cases
Patient 1 Patient 2 Patient 3
Management
Time before treatment (mo) 0.3 N/A 12
Hydroxycobalamin i.m. No IM
Betaine Yes No Yes
Folinic acid Yes No Yes
Other treatment Plasma exchange Solumedrol No Eculizuma
Outcome after treatment
Stop hemolysis Yes N/A Yes
Time (days) 7 0
Weaning off dialysis Yes No Yes
Time (mo) 5 3
Relapse No N/A No
Time (yr)
Dialysis No N/A No
Time (yr)
Kidney transplantation No N/A No
Time (yr)
Relapse on graft
Death No Yes No
Time (yr) 1
i.m., intramuscular; N/A, not applicable; NA, not available; SC, subcutaneous.
4
FLA 5.5.0 DTD  EKIR368_proof  30and partially. One patient was treated with eculizumab
without any improvement.
Patient 7 had an atypical history. She was diagnosed
with a renal TMA during pregnancy and received a
kidney transplant 5 years later. The diagnosis of cblC
deﬁciency was made 9 months later, after the recur-
rence of TMA on the graft. She received a second
kidney transplant 6 years after the diagnosis.
One patient relapsed 5 years after treatment initia-
tion because of inobservance. None of the 2 patients
who had undergone transplantation relapsed on the
kidney graft under treatment.Histopathological Characteristics of Renal
Disease
Nine biopsies Qwere available for the 7 patients
(Supplementary Table S1). Light microscopic evaluation
revealed glomerular and arteriolar TMA in all patients.
Most of the glomeruli presented typical lesions of
TMA (Figure 2), with thickening of the capillary wall
(Figure 2a) in all patients and intraglomerular thrombi
in 3 patients (Figure 2b). Remodeling of the glomerular
basement membrane (GBM), deﬁned as duplication
and/or a vacuolar aspect of the GBM, was seen in 6
patients altogether. Typical duplication of the GBM
was seen in 2 patients at diagnosis, but was also noted
in the 2 biopsies performed during the follow-up
(Figure 2c). The GBM vacuoles (Figure 3a) were
particularly frequent, as they were present in 6
patients. Microaneurysm, mesangial sclerosis, endoca-
pillary proliferation, and glomerular ischemia werePatient 4 Patient 5 Patient 6 Patient 7
18 4 1 84
SC SC IM IM
Yes Yes Yes Yes
Yes Yes Yes Yes
b Plasma exchange No Plasma exchange Plasma exchange
Yes Yes Yes Yes
30 30 NA NA
Yes N/A No N/A
0.8
Yes No No No
5
No No Yes Yes
0 5
No No Yes Yes
1 6
No No
No No No No
Kidney International Reports (2018) -, -–-
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Figure 2. Glomerular and arteriolar lesions of thrombotic microangiopathy in patients with cobalamin C (cblC) deﬁciency. (af) Kidney biopsy.
Light microscopy. (a) Arteriolar and glomerular thrombotic microangiopathy with thickening of capillary walls and arteriolar thrombus (patient 1;
Masson trichrome staining; original magniﬁcation, 400). (b) Global thickening of glomerular capillary walls and endocapillary glomerular
thrombi (patient 5; Masson trichrome staining; original magniﬁcation, 400). (c) Global thickening of glomerular capillary walls and duplication
of the glomerular basement membrane (patient 52 Q13; Jones staining; original magnification, 400). (d) Massive juxtaglomerular arteriolar and
glomerular thrombi (patient 6; Masson trichrome staining; original magnification, 400). (e) Glomerular ischemia and arteriolar fibrous plug
(patient 2; Jones staining; original magnification, 400). (f) Glomerular TMA and arteriole occluded by fibrosis infiltered by foamy cells (patient 1;
Masson trichrome staining; original magnification, 400).
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533seen in 2, 5, 3, and 4 patients, respectively. Synechiae
and extracapillary proliferation were not seen.
All the patients had vascular lesions of TMA. Intra-
vascular thrombi were present in all but one patient
(Figure 2d). Fibrous plugs (Figure 2e), ﬁbrous endar-
teritis (Figure 2f), and hyalinization were seen in 4, 3,
and 3 patients, respectively.
Five patients had interstitial ﬁbrosis with tubular
atrophy at diagnosis and all of them presented acute
tubular necrosis. The most severe lesions of interstitial
ﬁbrosis with tubular atrophy were found in the 2 pa-
tients who were not weaned off dialysis.
Two patients had a second biopsy during follow up,
1 patient a few months after treatment with eculizumab,
revealing an increase in tubulo-interstitial lesions, and 1Kidney International Reports (2018) -, -–-
FLA 5.5.0 DTD  EKIR368_proof  30patient 5 years after treatment by intramuscular OHCbl,
showing disappearance of thrombi but arteriolar hya-
linization. The kidney lesions found in the patient
presenting with a heterozygous mutation in comple-
ment factor H were similar to those of the other patients.
Immunoﬂuorescence reports are detailed in
Supplementary Table S2. All but 1 patient had light-to-
severe glomerular capillary wall IgM deposits
(Figure 3b). One patient had moderate endomembranous
C3 deposits, and no patient had IgG deposition.
Electron microscopy was performed in 1 patient
(patient 1). It showed thickening of the GBM with
vacuolated aspect (Figure 3c) due to intramembranous
granular deposits and mesangial extensions
(Figure 3d).5
534
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Figure 3. Vacuolated aspect of the glomerular basement membrane (GBM) due to IgM deposits in patients with cobalamin C deﬁciency. (a)
Light microscopy. Glomerular capillary wall thickening with vacuoles and spikes (patient 3; Jones staining; original magniﬁcation, 2000). (b)
Immunoﬂuorescence microscopy. Glomerular capillary wall granular IgM deposits (patient 1; immunoﬂuorescence staining for IgM; original
magniﬁcation, 400). (c,d) Electron microscopy. Patient 1. (c) Thickening of the glomerular capillary wall with intramembranous granular
deposits and material leading to the vacuolated aspect of the GBM (original magniﬁcation, 16,000). (d) Intramembranous granular deposits and
mesangial cell expansion in vacuolated GBM (original magniﬁcation, 50,000).
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642Comparison of Renal Histopathological Find-
ings Between cblC Deﬁciency and Other Causes
of TMA
The most frequent causes of cblC-independent TMA
were typical HUS, atypical HUS, and malignant hy-
pertension (Supplementary Table S3). There was no
difference in age (cblC 15.9  6.8 years vs. control 12.7
 7.2 years, P ¼ 0.3), dialysis (cblC, n ¼ 5 (71%) vs.
control, n ¼ 5 [33%], P ¼ 0.2) or proteinuria (cblC 4.5
 2.9 g/d vs. control 3.9  8.7 g/d, P ¼ 0.07) between
the 2 groups.
A comparison of the histopathological characteristics
between the 2 groups is reported in Table 3. There was
no difference in vascular and tubulo-interstitial lesions
between the 2 groups. It is interesting that among the
GBM remodeling lesions, we found that the vacuolated
appearance of the GBM was signiﬁcantly more frequent
in patients with cblC deﬁciency than in controls (cblC,
n ¼ 6 [86%] vs. controls, n ¼ 1 [7%], P < 0.001).
Immunoﬂuorescence study revealed that glomerular
IgM deposits were signiﬁcantly more frequent and
abundant among patients with cblC deﬁciency (cblC
1.8  0.8 vs. controls 0.4  0.5, P ¼ 0.003).
DISCUSSION
In this study, we found that cblC patients, as opposed
to renal TMA control patients, presented with a6
FLA 5.5.0 DTD  EKIR368_proof  30peculiar histopathological picture of the GBM associ-
ated with a vacuolated aspect and IgM deposits, in
addition to arteriolar and glomerular lesions of TMA.
Cobalamin C deﬁciency is the most common inheri-
ted disorder of vitamin B12 metabolism. Pediatricians
are usually aware of the multisystem disorders associ-
ated with early-onset cblC deﬁciency in infants. On the
contrary, the presentation in adults is generally not
recognized at an early stage due to limited knowledge
of this disorder, and patients with cblC deﬁciency
represent a diagnostic conundrum for the physicians
involved. Renal complications in patients with cblC
disease are a relatively rare entity, with 40 cases
described to date.7,11 Among them, the majority (24 of
40) presented with late-onset disease, including 12
adolescents or young adults. The most frequently re-
ported renal manifestation was TMA, although a few
cases describe an atypical glomerulopathy, considered
as glomerular consequences of TMA.12,13 Biological
screening of cblC deﬁciency is classically recommended
in children with TMA, but not in adults.14 However,
recent data highlight the interest for clinicians to
consider the diagnosis of cblC deﬁciency when renal
TMA is diagnosed in adolescents or young adults.1
Recently, Fakhouri et al. have proposed a diagnostic
algorithm suggesting that cblC deﬁciency must be
ruled out in STEC-negative QHUS, by the measurementKidney International Reports (2018) -, -–-
June 2018  2:36 pm  ce
Q8
Table 3. Comparison of histopathological ﬁndings between TMA
during cobalamin C (cblC) deﬁciency and other causes of TMA
Histological ﬁndings
cblC Deﬁciency
(n [ 7)
Control TMA
(n [ 16) P value
Glomerulus
Glomeruli with TMA
(% of glomeruli)
97.6  6.4 95.3  10.1 0.67
Sclerotic glomeruli
(% of glomeruli)
1.6  4.2 12.6  21.2 0.12
Thrombi (score) 0.7  1.1 0.6  1.0 0.72
Thickening of capillary wall 2  0.8 1.7  1.1 0.59
Microaneurysm 0.2  0.4 0.3  0.4 0.65
GBM remodeling n ¼ 6 (86%) n ¼ 7 (44%) 0,09
Duplication of GBM n ¼ 4 (57%) n ¼ 7 (44%) 0.34
GBM vacuoles n ¼ 6 (86%) n ¼ 1 (7%) <0.001
Mesangial sclerosis 1.3  0.9 1.2  1.0 0.72
Endocapillary proliferation 0.6  0.8 0.7  0.7 0.71
Synechiae 0 0.3  0.6 0.27
Ischemia 0.6  0.9 0.6  0.9 0.88
Extracapillary proliferation
(n of patients, %)
n ¼ 0 (0%) n ¼ 1 (6.3%) 0.9
MPGN aspect n ¼ 2 (29%) n ¼ 1 (6%) 0.21
Vessels
Interlobular arteries (score)
Thrombi 0.3  0.5 0.5  1.1 0.84
Fibrous endarteritis 0.3  0.5 0.7  1.2 0.9
Bulbiform FE 0.8  1.3 0 0.07
Juxtaglomerular arterioles (score)
Thrombi 1.1  0.7 0.8  0.9 0.29
Bulbiform FE 1  1.4 0.4  0.8 0.38
Fibrous plugs 1.3  1.4 0.5  0.9 0.19
Hyalinization (n of patients, %) n ¼ 1 (14%) n ¼ 1 (6%) 0.53
Tubules and interstitium (score)
Interstitial ﬁbrosis 1.6  0.9 1.3  1.0 0.59
Tubular atrophy 1.3  1.1 0.6  0.9 0.17
Acute tubular necrosis 1.6  0.9 0.8  1.2 0.12
IgM deposits (score) 1.8  0.8 0.4  0.5 0.003
Results are expressed as mean  SD for qualitative variables (comparison with
MannWhitney U test) or as number (percentage) for quantitative variables (compar-
ison with Fisher exact test).
FE, ﬁbrous endarteritis; GBM, glomerular basement membrane; MPGN, mem-
branoproliferative glomerulonephritis; n, number; TMA, thrombotic microangiopathy.
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750of plasma homocysteine and urine or plasma methyl-
malonic acid, with or without MMACHC direct
sequencing.15 In our study, all but 1 patient were
weaned off dialysis after treatment initiation, which
supports the beneﬁt of identifying the diagnosis to
rapidly start the speciﬁc treatment.
Cobalamin C deﬁciency is due to mutations in
MMACHC gene, which is located on chromosome
1p343 and encodes a protein acting as a cyanocobalamin
decyanase.16 Among the 87 1mutations identiﬁed in
MMACHC,11 c.271dupA, resulting in a frame shift, is
the most frequently encountered (40%55%), and was
present in all patients analyzed in our study.3,17 Several
studies suggest a phenotypegenotype correlation,
and the homozygous c.271dupA mutation appears to be
associated with early-onset disease.17 In contrast, in
heterozygous patients, phenotype appears to beKidney International Reports (2018) -, -–-
FLA 5.5.0 DTD  EKIR368_proof  30determined by the less deleterious mutation.18 Indeed,
in this study, all patients presented with late-onset
disease and they all had at least 1 partially functional
allele (splice or missense mutation). The 2 other muta-
tions found in our work were the missense mutation
c.389A>G,17 which has rarely been reported, and the
splice mutation c.82-9_12delTTTC, which has been
described only in patients with renal TMA.18
The pathophysiology of TMA during cblC deﬁ-
ciency is not completely understood. Hyper-
homocysteinemia may play a crucial role in renal
vascular endothelial toxicity.19,20 It also alters the
antithrombotic properties of the endothelium, possibly
through impairing the nitric oxidemediated inhibi-
tion of platelet aggregation,21,22 and leads to increased
coagulation.23,24 However, the absence of reported
cases of TMA during cystathionine synthase deﬁ-
ciency,25 characterized by hyperhomocysteinemia with
hypermethioninemia, highlights the existence of addi-
tional factors. Thus, hypomethioninemia may play a
role in small vessel injury. In our population, plasma
exchange partially improved hemolysis and kidney
function in 3 patients, which may suggest a beneﬁcial
role of the clearance of a potential circulating factor.
Another interesting point is the atypical history of
patient 7, in whom the diagnosis was made after a ﬁrst
kidney transplantation. To our knowledge, cblC-
related HUS had not yet been reported after kidney
transplantation. This case holds important pathophys-
iological implications, as it strongly supports the role of
plasma disturbances in TMA, as opposed to the hy-
pothesis of a primitive involvement of cblC deﬁciency
in vascular endothelial injury at the cellular level. HUS
have also been described in cblG26 and cblE disease,27
characterized by hyperhomocysteinemia without
MMA, whereas only tubulo-interstitial injuries have
been reported during MMA without hyper-
homocysteinemia.28 These 2 points remove the poten-
tial role of urine or plasma methylmalonic acid.
Associated factors of TMA should also be searched,
such as complement alternative pathway abnormal-
ities,8,29 which may participate in endothelial injury in
selected cases.
The pathophysiology of TMA during cblC deﬁ-
ciency is supposed to be similar to the pathophysi-
ology of PAH and communicating hydrocephalus.30
However, in our population, no patient presented
with hydrocephaly, and only 1 patient had a history
of neurological abnormality, revealed by a language
delay. The clinical features are atypical in our study
because neurological signs are usually the most
frequent symptoms at onset or during course of cblC
deﬁciency.31 This conﬁrms the wide heterogeneity of
cblC disease, and that the diagnosis has to be evoked7
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858even in the absence of neurologic damage.32 Like-
wise, only 1 patient presented with PAH in our
study, but several cases of PAH during cblC deﬁ-
ciency have been reported, frequently associated
with TMA.33,34
Our histopathological study revealed arteriolar and
glomerular TMA in all cblC patients described, with
typical acute and chronic lesions. In their recent review,
Beck et al. retrospectively reported the results of 16
biopsies of cblC patients.11 The authors described
glomerular TMA lesions with endothelial swelling,
glomerular thrombi, and/or duplication of the GBM. In
the latter study, there was no immunoﬂuorescence
analysis, centralized review or control population. In the
present study, we showed that GBM vacuoles and IgM
deposition were signiﬁcantly more frequent in patients
with cblC disease, compared to a control population
with cblC-independent TMA. Vacuolated GBM has not
yet been reported in cblC patients, but IgM deposits
have already been described in 3 patients.12,35 GBM
remodelling, including vacuoles, can be seen in chronic
TMA. In this study, there was no difference regarding
the time from clinical diagnosis of TMA to biopsy be-
tween the 2 groups. However, due to the genetically
driven pathophysiology of the disease, we can suppose
that, as opposed to some cblC-independent TMA pa-
tients, the cblC patients presented ongoing lesions years
before the diagnosis was made. These ﬁndings correlate
with the late-onset presentation of the disease in our
patients, in which diagnosis is made late because of
subacute presentation. This chronic evolution could also
explain that cblC patient had relatively normal platelets
level, which has already been described in several case
reports.33,35,36 Red blood cell count is also almost normal
in our study, and schizocytes, LDH elevation, or low
haptoglobin is the only hint to TMA. Cobalamin C
deﬁciency is not an immune-related disease, and no
study has yet focused on immune deposits in this dis-
order. In the few cases reporting the results of autopsy in
patients with cblC defect, there are no data on immu-
noﬂuorescence in other organs.37,38 Due to the similar
histopathological pattern, we can speculate that the
vacuolated aspect is secondary to deposits, as occurs in
membranous nephropathy. This is supported by the
ultrastructural study revealing intramembranous gran-
ular deposits, although electron microscopy was avail-
able in only 1 patient. In cblC-dependent TMA,
endothelial cell injury, especially oxidative stress
mediated by hyperhomocysteinemia, may involve
complement activation,39 and leucocyte aggregation,40
leading to deposits of IgM on the external face of the
GBM.We can also speculate that circulating IgM, due to
its biochemical characteristics, could be nonspeciﬁcally
trapped within the glomerular lesions.8
FLA 5.5.0 DTD  EKIR368_proof  30This retrospective study is limited mainly by the
relatively small number of patients included, due to the
rarity of the disease. The strength of this study lies
both in the detailed systematic histopathological anal-
ysis and in the comparison with cblC-independent
TMA, which identiﬁes typical renal lesions occurring
in late-onset cblC deﬁciency. These original results
provide novel information for pathologists, who should
speciﬁcally evoke the diagnosis of cblC deﬁciency
when kidney biopsy reveals TMA lesions associated
with a vacuolated aspect of the GBM and/or IgM de-
posits. Dosage of plasma homocysteine, methylmalonic
acid, and methionine are easy and inexpensive pro-
cedures that can highlight a misdiagnosed entity in
which prognosis is highly linked to the rapidity of
treatment initiation. When the diagnosis of cblC deﬁ-
ciency is biochemically suspected, MMACHC direct
sequencing allows one to afﬁrm the diagnosis, but the
speciﬁc treatment, including intramuscular injections
of OHCbl, betaine, and folinic acid,5 must be rapidly
started, without waiting for conﬁrmatory testing.
In conclusion, w Qe suggest that all the patients with
renal TMA be screened for cobalamin metabolism dis-
order with plasma homocysteine measurement,
regardless of age at presentation, particularly when
microscopy reveals a vacuolated aspect of the GBM and
glomerular capillary wall IgM deposition.DISCLOSURE
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